DeutschNewstral
Article
Bbarrons.com on 2020-05-27 16:45
What Sanofi Might Buy With Its Regeneron Windfall
Related news
- MRegeneron to buy back $5 billion in stock as Sanofi sells part of its stakemarketwatch.com
- BRegeneron Is Finally Free of Sanofi. Why That’s Good for Its Stock.barrons.com
- BA Case to Buy Regeneron Stock After Its Recent Tumblebarrons.com
- BDupixent Is Big for Sanofi and Regeneron, Analysts Writebarrons.com
Regeneron, Sanofi increase investment in drug developmentswestfaironline.com- BBuy Regeneron Stock, but Not Because of Its Covid-19 Antibody Cocktail, Analyst Saysbarrons.com
- BSanofi Is a Buy Because of Its Drug Pipeline, Analyst Saysbarrons.com
- Regeneron, Sanofi announce positive results for food allergy drugwestfaironline.com
- BRegeneron Will Buy Cancer Drug Rights From Sanofi for Up to $1.1 Billion1 min readbarrons.com
- BSanofi, Regeneron Give Up on Arthritis Drug in Covid-19. Why That’s OK.barrons.com
- MSanofi, Regeneron shares Pop, information exhibits bronchial asthma drug Dupixent can deal with COPDmvtelegraph.com
- Regeneron, Sanofi restructure Kevzara, Praluent collaborationwestfaironline.com
Feds approve Regeneron, Sanofi skin cancer drugbizjournals.com- BRegeneron Stock Has Hit Its Peak, Says Citibarrons.com
Alnylam soars as Sanofi weighs its optionsThe Salt Lake Tribune- BRegeneron Stock Jumps After Analyst Says Now Could Be a Good Time to Buybarrons.com
Boehringer gains conditional EU okay to buy Sanofi unitReuters- FDA approves Regeneron, Sanofi skin cancer immuno-oncology drugwestfaironline.com
- PAmgen wins lawsuit against Regeneron, Sanofi for violating patentspacbiztimes.com
No early win for Sanofi, Regeneron cholesterol drug in studymetro.us